Inova Translational Medicine Institute CEO Dr. John Niederhuber Discusses Genomics and the Future of Healthcare at NVTC Titans Breakfast
On April 9, about 400 members of the region's technology community gathered at The Ritz-Carlton, Tysons Corner for a Titans breakfast featuring Inova Translational Medicine Institute (ITMI) CEO Dr. John Niederhuber. Niederhuber, who is a nationally renowned surgeon and researcher who has dedicated his four-decade career to the treatment and study of cancer, participated in a fireside chat with NVTC Vice Chair Todd Stottlemyer.
|Dr. John Niederhuber, CEO of the Inova Translational Medicine Institute (ITMI), addresses the Titans audience on April 9, 2015.|
According to Niederhuber, our ability to store and analyze increasing amounts of data has been key to recent advances in genomics research and treatment. Technology will continue to be critical to progress in the field of genomics, he said, predicting that in ten or fifteen years, everyone will be wearing devices that monitor our health in real time.
|Niederhuber and NVTC Vice Chair Todd Stottlemyer|
during the April 9 Titans fireside chat.
In discussing the growth and future of the ITMI, Niederhuber explained the challenges of developing its genomics work from the research sequencing stage to data analysis and clinical use, as well as the need to raise funds to support ITMI's work. A research team that is passionate about the effort is one factor working in favor of ITMI's success, he said. Having partners from the business community interested in helping "push the science forward" will also be crucial. However, Neiderhuber is optimistic about the opportunity for collaboration, claiming that the region's unique mix of assets and capabilities gives us an edge over other regions.